Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00437853|
Recruitment Status : Completed
First Posted : February 21, 2007
Last Update Posted : February 21, 2007
EFFICACY OF NEOADJUVANT ENDOCRINE THERAPY WITH ANASTROZOLE IN POMENOPAUSAL WOMEN WITH ER-POSITIVE BREAST CANCER.
Flavia Morales-Vásquez, Horacio Noé López Basave.
Background: Neoadjuvant Hormonal Therapy (HT) is being used increasingly to downstage locally advanced and large operable breast cancer. Following this treatment, inoperable breast cancer often becomes fully respectable and tumors requiring mastectomy may be successfully removed by breast-conserving surgery (BCS).
Methods: Recruit postmenopausal women with ER(+) and/or PgR (+) breast cancer (BC) T2,N1-2 to T3,N0-1 were assigned to HT with anastrozole 1 mgr daily for 4 months.
The primary endpoint was to compare overall objective response (OR) determined by clinical (palpation) and ultrasound. Secondary endpoint was the number of patients who qualified for BCS plus radiotherapy.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: Anastrozole||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||June 2003|
|Study Completion Date :||February 2007|
- The primary endpoint was to compare overall objective response (OR) determined by clinical (palpation) and ultrasound.
- Secondary endpoint was the number of patients who qualified for BCS plus radiotherapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00437853
|Instituto Nacional de Cancerologia de Mexico|
|Mexico D.F., Mexico, D.F., Mexico, 14080|
|Principal Investigator:||Flavia Morales-Vasquez||Instituto Nacional de Cancerologia Mexico|
|Study Director:||Alejandro Mohar||Instituto Nacional de Cancerologia Mexico|
|Study Chair:||Alfonso Dueñas Gonzalez||Instituto Nacional de Cancerología|